TOKAI (9729) Q4 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2026 earnings summary
12 May, 2026Executive summary
Consolidated net sales grew 6.8% year-over-year to ¥159,664 million, marking a fifth consecutive annual increase and a new record high.
Operating profit rose 14.5% year-over-year to ¥9,382 million, also reaching a record high, with all profit lines exceeding initial plans.
Profit attributable to owners of parent surged 28.3% year-over-year to ¥6,069 million.
Comprehensive income increased 72.1% year-over-year to ¥7,009 million.
Capital efficiency improved, with ROE rising to 7.2% (up 1.7pp YoY) following a share buyback and cancellation.
Financial highlights
Net sales: ¥159,664mn (+6.8% YoY, +1.1% vs. plan); operating profit: ¥9,382mn (+14.5% YoY, +14.2% vs. plan); ordinary profit: ¥10,098mn (+14.4% YoY); profit attributable to owners: ¥6,069mn (+28.3% YoY).
Gross profit improved to ¥38,779 million from ¥35,439 million year-over-year.
Basic earnings per share rose to ¥185.61 from ¥138.97 year-over-year.
Cash flows from operating activities hit a new record high at ¥11,442 million.
Cash and cash equivalents at period end: ¥23,417mn.
Outlook and guidance
FY3/27 net sales forecast at ¥165,400mn (+3.6% YoY); operating profit expected to decline 4.2% due to fee revisions and cost pressures.
Profit attributable to owners projected to rise 0.8% YoY, reflecting absence of impairment losses.
Basic earnings per share forecasted at ¥198.08 for the next fiscal year.
Annual dividend per share forecasted to increase to ¥80.00.
Mid-term sales goal set at ¥170bn.
Latest events from TOKAI
- Record sales and profit growth, driven by rental, pharmacy, M&A, and special dividends.9729
Q3 202612 Feb 2026 - Record sales and profit growth, higher dividends, and capital returns planned.9729
Q2 202611 Nov 2025 - Record sales and operating profit, but net profit fell; outlook and dividend raised.9729
Q1 20267 Aug 2025 - Net sales and net income increased, but full-year profit is forecast to decline.9729
Q2 202513 Jun 2025 - Sales and profits rose, with strong Q1 gains and stable full-year outlook.9729
Q1 202513 Jun 2025 - Record sales and profit growth, but net income fell on impairments; outlook remains positive.9729
Q4 20256 Jun 2025 - Record sales growth, but profit pressured by higher costs and securities losses.9729
Q3 20255 Jun 2025